Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice by de Groot, John F. et al.
Tumor invasion after treatment of
glioblastoma with bevacizumab: radiographic
and pathologic correlation in humans and
mice
John F. de Groot, Gregory Fuller, Ashok J. Kumar, Yuji Piao, Karina Eterovic, Yongjie Ji,
and Charles A. Conrad
Brain Tumor Center (J.F.G., Y.P., K.E., Y.J., C.A.C.); Department of Neuropathology (G.F.); Department of
Neuroradiology (A.J.K.), The University of Texas M. D. Anderson Cancer Center, Houston, Texas
Patients with recurrent malignant glioma treated with
bevacizumab, a monoclonal antibody to vascular endo-
thelial growth factor (VEGF), alone or in combination
with irinotecan have had impressive reductions in MRI
contrast enhancement and vasogenic edema. Responses
to this regimen, as deﬁned by a decrease in contrast
enhancement, have led to signiﬁcant improvements in
progression-free survival rates but not in overall survival
duration. Some patients for whom this treatment regimen
fails have an uncharacteristic pattern of tumor pro-
gression, which can be observed radiographically as an
increase in hyperintensityonT2-weightedorﬂuid-attenu-
ated inverse recovery (FLAIR) MRI. To date, there have
been no reports of paired correlations between radio-
graphic results and histopathologic ﬁndings describing
the features of this aggressive tumor phenotype. In this
study, we correlate such ﬁndings for 3 illustrative cases
of gliomas that demonstrated an apparent phenotypic
shift to a predominantly inﬁltrative pattern of tumor pro-
gression after treatment with bevacizumab. Pathologic
examination of abnormal FLAIR areas on MRI revealed
inﬁltrative tumor with areas of thin-walled blood
vessels, suggesting vascular “normalization,” which was
uncharacteristically adjacent to regions of necrosis.
High levels of insulin-like growth factor binding
protein-2 and matrix metalloprotease-2 expression were
seen within the inﬁltrating tumor. In an attempt to
better understand this inﬁltrative phenotype associated
with anti-VEGF therapy, we forced a highly angiogenic,
noninvasive orthotopic U87 xenograft tumor to become
inﬁltrative by treating the mice with bevacizumab. This
model mimicked many of the histopathologic ﬁndings
from the human cases and will augment the discovery
of alternative or additive therapies to prevent this type
of tumor recurrence in clinical practice.
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T
he prognosis of patients with malignant gliomas
remains poor despite decades of basic and clinical
research. Median survival durations are approxi-
mately 12–14 months for patients diagnosed with glio-
blastoma
1,2 and 3–5 years for patients diagnosed with
anaplastic astrocytoma.
3 Because high-grade gliomas
are highly angiogenic, there is a convincing rationale
for targeting the tumor vasculature. High-grade
gliomas secrete large amounts of vascular endothelial
growth factor (VEGF), which acts in a paracrine
manner to promote endothelial cell proliferation, survi-
val, and migration.
4 Inhibiting VEGF is an effective
anticancer therapy,
5–7 and several clinical trials have
demonstrated a high response rate and improvements
in progression-free survival rate in patients with recur-
rent glioblastoma treated with bevacizumab, with or
without irinotecan,
8–10 compared with outcomes for
historical controls.
2 VEGF receptor inhibitors also
have activity against glioblastoma, as demonstrated in
a recent study of the pan-VEGF receptor tyrosine
kinase inhibitor cediranib (also called AZD2171 or
Recentin, AstraZeneca), in which radiographic response
rates were approximately 50% and the 6-month
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11 Surprisingly,
VEGF and VEGF receptor inhibitors have resulted in
little improvement in overall survival duration,
12 and
tumors that progress during bevacizumab therapy are
highly resistant to subsequent therapies.
13
Blocking VEGF has been shown to prune abnormal
tumor blood vessels and “normalize” the remaining vas-
culature.
14 Although vascular permeability is decreased
within the tumor, it has been hypothesized that vascular
normalization temporarily improves oxygen and drug
delivery to the tumor,
14–16 thereby improving treatment
efﬁcacy. Reduced vascular permeability has several clini-
cal beneﬁts, including decreasing cerebral edema and
accompanying neurologic symptoms, allowing patients
to minimize corticosteroid use.
11 However, changes in
vascular permeability measured through dynamic
contrast-enhanced MRI do not predict the long-term
outcome of patients who receive bevacizumab,
17
suggesting that decreases in permeability are necessary
but not sufﬁcient to produce long-term responses.
Glioblastoma rapidly adapts to anti-VEGF therapy,
leading to rapid tumor progression without improve-
ment in overall survival.
The purpose of this study was to investigate the phe-
notypic change in radiographic tumor progression that
has been observed in some patients receiving bevacizu-
mab. We describe 3 patients who, during bevacizumab
therapy, developed inﬁltrative lesions visible by MRI.
Tumor tissue was obtained from these patients during
treatment and, for the ﬁrst time, we present data that
pair imaging features seen on MRI with histopathologic
ﬁndings. We found a decrease in tumor vascularity and
lack of glomeruloid endothelial proliferation within
the tumor. Blood vessels with walls of a single layer of
endothelial cells were present, consistent with vascular
normalization. Interestingly, these more normal-
appearing vessels were found immediately adjacent to
the areas of tumor necrosis. At the leading edge of the
tumor, we were not able to demonstrate perivascular
tumor invasion. To better understand the tumor
biology of progression during, or “escape” from,
anti-VEGF therapy, we further substantiated our ﬁnd-
ings in a murine orthotopic xenograft model derived
from U87 glioma cells. We found that prolonged
anti-VEGF treatment led to tumor invasion through
perivascular and subpial tumor invasion. These ﬁndings
will augment the discovery of potential mechanisms of
tumor invasion and aid in the development of drug com-
binations to treat or prevent this phenotypic shift.
Patients and Methods
Patients
We identiﬁed 3 patients for whom a pattern of non-
enhancing (non–contrast-enhancing) tumor inﬁltration
was the mechanism of tumor progression during bevaci-
zumab treatment for biopsy-proven recurrent disease.
These 3 patients were selected for careful neuroradiolo-
gic review of all MRI sequences by one of our
neuroradiologists (A.J.K.). Using MRI studies, the area
of the largest lesion of progressive disease at the level
of the maximum bidimensional measurement was
determined for each patient. Both gadolinium
contrast-enhanced images and noncontrast ﬂuid-
attenuated inverse recovery (FLAIR) sequences were
used for these measurements. The change in area from
that measured on the pretreatment MRI image or on
the last stable MRI image available was recorded and
was expressed as a percentage change, as described pre-
viously.
18 These patients were determined to have had
bidimensional measurement increases of greater than
25% at the time of treatment failure. In all 3 cases,
more than 6 months had passed between completing
radiation therapy and starting bevacizumab. The inter-
val between the last dose of bevacizumab and the
surgery to remove the recurrent tumor was less than
30 days in all 3 cases. For this study, informed consent
was obtained for patients and was approved by the
University of Texas M. D. Anderson Cancer Center
Institutional Review Board.
Mouse Xenograft Orthotopic Models
All animal experiments utilized the U87 glioma cell line,
which was obtained from the American Type Culture
Collection. U87 tumor cells were implanted into nude
mice by the screw-guided method as described pre-
viously.
19 Beginning 5 days after tumor implantation,
animals were treated with bevacizumab at 10 mg/kg
i.p. twice weekly or IgG at 10 mg/kg i.p. twice weekly
(as a control). Animals were observed closely for signs
of clinical deterioration, at which time they were killed
in accordance with the regulations and guidelines of
the Institutional Animal Care and Use Committee
(IACUC). All experiments were approved by the
animal care and use committee of the M. D. Anderson
Cancer Center. After euthanasia, tumors were extracted,
ﬁxed in formalin, and then parafﬁn embedded.
Immunohistochemistry
Immunohistochemical analysis of total insulin-like
growth factor binding protein-2 (IGFBP2), matrix
metalloprotease-2 (MMP2), carbonic anhydrase IX
(CA9), and factor VIII was performed on
parafﬁn-embedded, formalin-ﬁxed xenograft and
human tumor tissue. Brieﬂy, 5-mm-thick sections were
mounted on positively charged slides, deparafﬁnized,
and rehydrated in phosphate-buffered saline (PBS).
Endogenous peroxidase activity was blocked with 3%
hydrogen peroxide in PBS/0.05% Tween 20 for 20
minutes. Sections were then washed in PBS and blocked
for 20 minutes in the appropriate serum from the same
species as the secondary antibody, diluted to 10% in
PBS. Microwave antigen retrieval was performed by
placing the slides in 50 mM citrate buffer (pH 6.0) and
microwaving for 12 minutes at full power and 10
minutes at 20% power, followed by cooling for 15
minutes and washing in PBS 2–3 times for 5 minutes
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were applied to the sections in a humid chamber over-
night at 488C. Secondary antibodies were applied using
the Dako EnVision kit (Carpinteria, CA) according to
the manufacturer’s instructions. Detection of bound sec-
ondary antibody was performed with diaminobenzidine.
Sections were then counterstained with light hematoxylin
and mounted. The primary antibodies used were as
follows: IGFBP2 (Santa Cruz Biotechnology, Santa
Cruz, CA), factor Vlll (catalog number A0082, Dako),
CA9 (Novus Biologicals, Littleton, CO), and MMP2
(sc-6838, Santa Cruz Biotechnology).
Results
Human Radiographic Imaging and Pathologic
Correlation
Case 1. The ﬁrst patient was a 31-year-old man who was
diagnosed with a right posterior frontal–anterior parie-
tal lobe glioblastoma followed by chemoradiation with
concurrent temozolomide followed by adjuvant temozo-
lomide. The patient had rapid progression and under-
went a second surgical resection. After surgery and
documentation of tumor progression, he was enrolled
onto protocol to receive temozolomide and Hominex
(a methionine-restricted diet). The patient received 2
cycles of treatment and then, when disease progressed,
underwent a third surgical resection. He then received
off-protocol 6-thioguanine, lomustine, capecitabine,
chloroquine, imatinib, and hydroxyurea and did well
for 13 months until a recurrence was noted in April
2006.
At this time, the patient began treatment with bevaci-
zumab and irinotecan and had a complete response,
which lasted from April 2006 until March 2007. The
initial response is shown in Fig. 1 (compare panels A
and B, taken before bevacizumab treatment, with
panels C and D, taken 3 months later after bevacizumab
treatment). There were marked decreases in vascular
permeability (visualized as enhancement) on the
contrast-enhanced MRI images and in vasogenic
edema on the FLAIR images. The patient then experi-
enced clinical decline consisting of increased left-sided
weakness, daytime fatigue, and a decrease in mobility.
The MRI scans dated March 1, 2007 (Fig. 1E), show
that the lack of vascular permeability had persisted
(there was no evidence of contrast enhancement);
however, there was an increase in the amount of inﬁltra-
tive disease (Fig. 1F, arrows), with swollen inﬁltrative
gyri. The patient’s therapy was discontinued, and a
Fig. 1. MR images from case 1. (A, C, E, and G) Postcontrast axial T1-weighted MR images. (B, D, F, and H) FLAIR MR images. (A and B)
Images taken 18 months after 2 surgeries, radiation therapy, and chemotherapy for recurrent glioblastoma. An inhomogeneously enhancing
area with necrosis (arrow in A) was seen posterior to the right frontal lobe surgical cavity, with a large area of surrounding edema (“E” in B).
(C and D) Images taken 3 months after beginning bevacizumab therapy. The enhancement posterior to the right frontal lobe surgical cavity
had disappeared, and there was a signiﬁcant decrease in the surrounding edema (“E” in D). (E and F) Images taken 8 months after starting
bevacizumab therapy. Subtle areas of nonenhancing FLAIR changes (arrows in F) were seen posterior to the surgical cavity, consistent with
nonenhancing tumor. (G and H) Images taken approximately 2 months after stopping bevacizumab. Signiﬁcant progression of
nonenhancing tumor (arrows in H) and spotty areas of enhancing tumor (arrows in G) were seen. The approximate biopsy site is
indicated by the white asterisk.
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strated deﬁnite inﬁltrative glioma. The biopsy specimen
taken from this nonenhancing tumor lacked signiﬁcant
vascular proliferation but was densely cellular. A
repeat MRI scan approximately 2 months later, dated
May 17, 2007, showed an increase in enhancement
(Fig. 1G and H) with an increase in inﬁltrative bulky
disease (arrows).
Case 2. The second patient was a 64-year-old man orig-
inally diagnosed with an anaplastic astrocytoma of the
left frontal lobe in December 2004. After surgery, he
underwent chemoradiation with adjuvant temozolo-
mide. He then was treated with multiple regimens,
including thalidomide plus irinotecan and the combi-
nation of 6-thioguanine, lomustine, capecitabine, and
chloroquine, but tumor progression occurred on this
regimen. He started bevacizumab and irinotecan treat-
ment and had a complete response, as demonstrated by
the absence of contrast-enhancing tumor (compare
Fig. 2A, taken April 20, 2006, before bevacizumab,
and C, taken October 3, 2006, after bevacizumab).
Vasogenic edema also improved (compare Fig. 2B and
D). The patient had slow progression of his neurologic
symptoms of fatigue, decreased memory, and loss of
executive functions. The MRI scans dated January 8,
2007, demonstrate a lack of contrast enhancement
(Fig. 2E), but a deﬁnite increase in the amount of
non–contrast-enhancing inﬁltrative disease (Fig. 2F,
arrows). A stereotactic biopsy on March 2, 2007,
demonstrated areas of necrosis and viable diffuse inﬁl-
trative glioma.
Case 3. The third patient was a 19-year-old man who
was diagnosed with a bifrontal glioblastoma. He was
treated postoperatively with chemoradiation with con-
current temozolomide followed by temozolomide, thali-
domide, and isotretinoin for atotal of 12 cycles. An MRI
scan revealed recurrent disease, so he was placed on a
regimen of carboplatin plus bevacizumab. This patient
had a dramatic improvement in the amount of
contrast-enhancing tumor (arrows) (compare Fig. 3A,
taken November 14, 2006, before bevacizumab, and
C, a 2-month post-treatment follow-up scan taken
January 16, 2007). In an MRI scan taken March 12,
2007, there was a lack of change in contrast enhance-
ment (Fig. 3D and F, arrows) but an increase in the
non–contrast-enhancing inﬁltrative component of the
tumor. The patient’s symptoms worsened, with
increased abulia, fatigue, and headache. Surgical resec-
tion on May21, 2007, revealed histopathologic evidence
of inﬁltrative high-grade tumor.
Histologic and Molecular Tumor Analysis
Tumor tissue samples were taken from the 3 patients
whose tumors progressed during anti-VEGF therapy.
None of the cases had evidence of contrast-enhancing
tumors on MRI scans taken at the time of biopsy or
surgery. The tumor biopsies or surgical specimens were
taken from areas of FLAIR abnormality seen on MRI,
and in all cases histologic examination demonstrated
abundant glioblastoma tumor cell inﬁltration. There
was a striking lack of vascular proliferation with little
evidence of vascular hyperproliferation and no evidence
of glomeruloid vessels (Fig. 4A).
Comparison with the original surgical specimens
revealed that both the ﬁrst and third cases had abundant
glomeruloid vascular proliferation consistent with the
initial diagnosis of glioblastoma. The second case, orig-
inally diagnosed as a mixed anaplastic oligoastrocy-
toma, did not have vascular proliferation as would
have been expected from the histologic diagnosis.
However, at the time of bevacizumab treatment, the
patient’s clinical course had been rapid, there had been
multiple recurrences, and the tumor was contrast enhan-
cing, all suggesting that this patient’s initial grade III
tumor had transformed into a glioblastoma.
Single endothelial cell walled vessels were observed
in all cases, consistent with the normalization of tumor
vasculature after anti-VEGF therapy. Some of these
normalized vessels were adjacent to areas of necrosis
(Fig. 4A), a ﬁnding in sharp contrast to typical histo-
logic observations, in which robust angiogenesis
(mediated by VEGF secretion) is present around
areas of tumor necrosis. Tumor progression and necro-
sis (Fig. 4A and B, white arrows) were occurring sim-
ultaneously with vascular normalization and vessel
pruning. Areas identiﬁed by the neuropathologist as
corresponding to the leading edge of the tumor did
not show an increase in perivascular tumor inﬁltration
(Fig. 4A, black arrows). The most abundant ﬁnding on
histologic examination of the inﬁltrative tumor lesions
was the typical invasion of glioma cells into neuropil
(Fig. 5A, black arrows).
IGFBP2 has been identiﬁed as an important mediator
of glioma cell invasion.
20 IGFBP2 (Fig. 4B, black
arrows) expression was markedly elevated around
regions of necrosis in all 3 cases (Fig. 4B, white
arrows). Given the reported correlation between
IGFBP2 and MMP2 expression,
20 we also evaluated
MMP2 staining in bevacizumab-treated tumors. Very
high levels of MMP2 expression were observed in all 3
cases (Fig. 4C, black arrows). In addition, we stained
for factor VIII, which demonstrates endothelial cell pro-
liferation. Less factor VIII staining was observed in the
pathologic samples from our 3 patients treated with bev-
acizumab (Fig. 5A, white arrows). However, tumor
tissue from bevacizumab-treated mice at terminal
stages had very high levels of endothelial cell prolifer-
ation (Fig. 5C and D). Finally, evaluation of tumor
levels of hypoxia was performed using the marker
CA9. As shown in Fig. 5E and F, there were high levels
of hypoxia surrounding areas of necrosis within the
densely cellular tumor mass. Adjacent to these areas
were the previously described single endothelial cell
walled vessels, conﬁrming our suspicion that prolonged,
continuous antiangiogenic therapy can lead to increased
tumor hypoxia. No CA9 staining was present within
densely cellular regions of the initial diagnosis tumor
samples (data not shown).
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taken 1 year, 8 months after surgery, radiation therapy, and chemotherapy for an anaplastic mixed oligoastrocytoma in the left frontal lobe.
Small enhancing areas (arrows in A) were seen posterior to the left frontal lobe surgical cavity, with surrounding edema (“E” in B). (C and D)
Images taken 57 days after beginning bevacizumab therapy. Previously noted enhancing areas had disappeared, and there was a suggestion
of nonenhancing tumor (arrow in D). (E and F) Images taken 95 days after starting bevacizumab therapy. An increase in the area of
nonenhancing tumor (arrows in F) was evident, with an increase in edema. The approximate biopsy site is indicated by the white asterisk.
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To better understand the impact of anti-VEGF therapy
on glioma biology, we developed an animal model that
mimics the proinvasive effects of anti-VEGF treatments.
Mice bearing intracranial U87 xenografts and treated
with bevacizumab for 4–6 weeks developed a pattern
of tumor invasion similar to that described pre-
viously.
21–23 Compared with IgG-treated controls, the
bevacizumab-treated tumors had less vascular prolifer-
ation, as described previously. In contrast with the
tumor cell localization in the human pathologic
samples, in the mouse model, tumor cells were found
to have spread along the perivascular space (Fig. 5C
and D, white arrows) in areas adjacent to the tumor
mass. U87 tumors also invaded along the subpial
space, with tracking along Virchow–Robin spaces
back into the brain (not shown). In striking contrast to
the control-treated tumors (Fig. 5B), the tumors treated
with bevacizumab had very invasive borders (Figs. 5C
and 5D). This ﬁnding was similar to the invasive pheno-
type seen in the patient examples described above.
Immunohistochemical staining was performed in a par-
allel fashion as in the human cases, and expression pat-
terns for factor VIII (Figs. 5C and 5D, white arrows) and
MMP2 (Figs. 4C and 4D, black arrows) were strikingly
similar to those in the patients’ tumors.
Discussion
Antiangiogenic strategies for the treatment of high-grade
gliomas have a strong biologic rationale since these
tumors produce large amounts of VEGF and are highly
vascular. The idea that antiangiogenic therapies normal-
ize tumor vasculature has been eloquently demonstrated
in patients with glioblastoma in a recent trial with the
pan-VEGF receptor inhibitor cediranib. Batchelor
et al.
11 showed that patients’ tumors treated with cedir-
anib exhibited a decrease in contrast enhancement with
a concomitant decrease in vessel surface area and vessel
permeability on MRI. Preliminary analyses of tumor
tissue obtained from patients treated in that study
showed a decrease in vessel density and restoration of
Fig. 3. MR images from case 3. (A, C, E, and G) Axial postcontrast T1-weighted MR images. (B, D, F, and H) FLAIR MR images. (A and B)
Images taken 14 months after surgery, radiation therapy, and chemotherapy for bifrontal lobe glioblastoma that inﬁltrated across the genus
of the corpus callosum. The enhancing area was seen in the right frontal lobe, capping and inﬁltrating the right frontal horn (arrow in A).
Nonenhancing tumor within the corpus callosum (arrows in B) was better visualized in the FLAIR image. (C and D) Images taken 62 days
after beginning bevacizumab therapy. The enhancing area within the right frontal lobe showed signiﬁcant decrease (arrow in C), but the
nonenhancing tumor showed progression (arrows in D). (E and F) Images taken 117 days after beginning bevacizumab therapy. The
enhancing area within the right frontal lobe showed further decrease, but the nonenhancing tumor (arrows in F) showed progression. (G
and H) Images taken 175 days after initiating bevacizumab treatment. Marked tumor progression was evident by an increase in
nonenhancing tumor (arrows in H) and with a small component of enhancing tumor (arrow in G) producing subfalcine herniation. After
subtotal resection of the tumor on May 21, 2007, it was histologically proven to be glioblastoma.
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blood-brain barrier integrity, as measured by CD71
expression.
24 Similar changes in vasculature observed
on MRI, with an attendant reduction in circulating
VEGF levels, have been reported in patients with recur-
rent glioblastoma who received bevacizumab.
17
However, the histologic and vascular ﬁndings at the
time of bevacizumab treatment failure have not been
reported previously. Although clinical progression
occurs coincident with FLAIR-indicated progression on
MRI, this report is the ﬁrst to demonstrate that the
FLAIR changes are due to tumor inﬁltration.
Perivascular tumor invasion was present in our preclini-
cal model, but we did not observe this invasive pattern in
the human cases. We show for the ﬁrst time evidence of
vascular normalization despite ongoing tumor pro-
gression and identify IGFBP2 and MMP2 as 2 potential
mediators of the increased inﬁltrative pattern commonly
observed on MRI.
The unusual pattern of tumor progression depicted in
these cases is not typical of the radiographic pattern of
glioblastoma progression, which normally emerges as
both an increase in contrast-enhancing tumor as well
as an increase in inﬁltrative disease with accompanying
vasogenic edema. Several groups have observed that
patients who receive anti-VEGF therapy have tumor
progression that is non–contrast-enhancing. In one
recent study, there was a nonsigniﬁcant trend toward
an increase in nonenhancing tumor progression in
patients treated with bevacizumab compared with
those treated with nonantiangiogenic therapy.
13
Continuous blockade of VEGF-induced vascular pro-
liferation may promote tumor “escape” through vascu-
lar co-option, which may radiographically manifest
itself as inﬁltrative, nonenhancing FLAIR progression.
Although in our patients the areas of FLAIR progression
were concordant with histologic evidence of recurrent
inﬁltrative tumor, perivascular tumor invasion was not
evident in the patients’ pathologic samples.
There are many potential explanations for the discre-
pancy in perivascular invasion between the human cases
and our animal model. First, this type of tumor escape
may have been present but may not have been found
because of sample bias. Alternatively, perivascular
tumor invasion may be an early mechanism of tumor
escape and a less prominent pathologic feature as the
tumor progresses and utilizes multiple concurrent mech-
anisms of invasion. Third, glioma tumors may use vessel
co-option early to escape the effects of continuous VEGF
sequestration and at later stages the tumor may sustain
angiogenesis via alternative growth factor pathways.
Finally, glioma tumors are highly invasive at baseline,
Fig. 4. Results of stereotactic biopsy of nonenhancing areas for case 3. (A and B) Human tumor samples from case 3 after progression during
bevacizumab treatment. (A) Clearly visible areas of tumor necrosis (white arrow) and single endothelial cell walled vessels (black arrows).
10 magniﬁcation. (B) Noted were areas of necrosis (white arrows), which were adjacent to areas that were positive for
immunohistochemical staining for IGFBP2 (black arrows). 40 magniﬁcation. (C and D) Immunohistochemical staining for MMP2 after
treatment with bevacizumab. (C) In this specimen from case 3, the vasculature was composed of single endothelial cells (white arrow).
Next to these vessels, an increase in expression of MMP2 was seen (black arrows). 10 magniﬁcation. (D) In contrast, in the mouse
U87 orthotopic xenograft model, cellular areas that were more dense (white arrow) and the leading edge (black arrows) were seen,
which showed prominent staining for MMP2 (black arrows). 5 magniﬁcation.
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promote multiple types of tumor invasion, including
the more typical neuropil inﬁltration.
That chronic anti-VEGF therapy both maintains vas-
cular normalization and promotes tumor invasion has
profound implications for the treatment of glioblastoma.
It demonstrates that effective blocking of the vascular
component of the tumor is insufﬁcient for tumor
control because the nonenhancing inﬁltrative com-
ponent of the tumor is able to escape and to continue
to inﬁltrate the CNS “behind” the blood-brain barrier.
Newer agents that can effectively cross the blood-brain
barrier would be logical candidate drugs to add to the
combination of bevacizumab and irinotecan. Tumor
cells may adapt to the reduced ability to stimulate neo-
vascularization by co-opting the normal vasculature
and occupying the perivascular niche. It is interesting
to speculate that the perivascular niche may add to the
treatment resistance of these inﬁltrative cells, as has
been suggested for glioma tumor stem cells.
25 In this
Fig. 5. Comparison of effects of anti-VEGF treatment between human and animal specimens. (A) In the tissue from case 3, single endothelial
cell wall vasculature was clearly highlighted after staining for factor VIII (5 magniﬁcation). (B–D) The U87 orthotopic xenograft model
demonstrated striking changes after bevacizumab treatment. (B) Hematoxylin and eosin staining (2.5 magniﬁcation) demonstrated
typical (control) growth of U87 cells in the mouse brain, with a sharply deﬁned leading edge of the tumor (white arrows). (C) In
contrast, in animals treated with bevacizumab, tumor growth was inﬁltrative in nature (2.5 magniﬁcation). Factor VIII staining
highlighted the robust clusters of vessels in the inﬁltrating tumor. (D) A higher magniﬁcation (10) of this inﬁltrating leading edge of
the mouse xenograft tumor. Particularly important are the extension and inﬁltration of tumor cells beyond the dense vasculature (white
arrows). The perivascular invasion noted in C and D contrasted with the more inﬁltrative growth pattern seen in the human tumor
samples. CA9 staining in human (E) and U87 xenograft (F) tumor tissue. Prolonged, continuous antiangiogenic treatment signiﬁcantly
increased CA9 staining in tumor. Note the areas of necrosis and hypoxia adjacent to single endothelial cell vasculature (black arrows)
and the dilated vessel with surrounding ﬁbrosis.
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tion and energy requirements. This progressive and
resistant phenotype is difﬁcult to treat, suggesting that
these tumor cells are capable of progressing even when
effective antiangiogenic therapy is being applied. Our
experience and that of others are that there are currently
no effective therapies that can block this tumor inﬁltra-
tion.
13 Since MMP expression around blood vessels
has been implicated in the normalization process after
anti-VEGF therapy,
16 and Src expression regulates
MMP2 release,
26 Src inhibitors may have a role in the
inhibition of anti–VEGF-induced invasion.
One of the most striking ﬁndings in our study was the
pathologic ﬁnding that “normal”-appearing tumor
vessels (single endothelial cell walled vessels) existed
adjacent to areas of tumor necrosis. Typically, an area
of tumor necrosis is induced by rapidly growing
tumor, which depletes nutrients and oxygen, ultimately
resulting in tumor hypoxia. This hypoxia leads to
increased VEGF production and ensuing ﬂorid vascular
proliferation. It has been suggested that antiangiogenic
therapy leads to vascular normalization, with the
expected consequence of improving oxygen delivery
and potentially increasing drug delivery to tumor.
14,27
These changes are expected to occur within a transient
“window” of time.
14 However, long-term antiangio-
genic treatments may also lead to an increase in tumor
hypoxia
28 as suggested by the profound CA9 staining
seen in our bevacizumab-failure cases, presumably due
to a decrease in tumor oxygenation, which has been
shown to increase tumor invasion in animal models.
22
The resultant decrease in blood ﬂow may also decrease
nutrient delivery, placing additional physiologic stress
on the tumor, which may contribute to the phenotypic
shift of the tumor becoming more invasive.
Furthermore, antiangiogenic agents may decrease drug
delivery to glioblastoma tumors,
29,30 which could be
one reason for the lack of efﬁcacy of changing the
chemotherapy regimen for patients whose disease
progresses during bevacizumab treatment. Finally,
during prolongedperiods of anti-VEGF therapy, alterna-
tive mechanisms of angiogenesis involving ﬁbroblast
growth factor, platelet-derived growth factor, and
other endothelial growth factors may partially reconsti-
tute the vasculature and ameliorate oxygen and nutrient
stress.
11,31,32 Fibroblast growth factor has been shown
to be important in the migration and invasion of some
tumors,
33 and an increase in its expression during
VEGF blockade could lead to a similar effect in glioma.
The pathologic ﬁndings described in this report have
critical implications for the care of patients with recur-
rent glioblastoma.A better understanding of the biologic
basis leading to these pathologic changes is essential and
may provide key insights into approaches to improving
the overall survival of these patients. If IGFBP2 and
MMP2 are conﬁrmed to be molecular mediators of
tumor evasion of anti-VEGF therapy, then combination
strategies can be designed to inhibit these targets. Better
methods of predicting which patients are likely to
develop these changes and improved radiologic
measures for detecting tumor invasion are also impor-
tant in improving care for patients receiving antiangio-
genic therapy. Our animal model that simulates the
human clinical scenario will be a useful tool as we
dissect the causes of and develop effective treatment
strategies for these unintended consequences of antian-
giogenic therapy.
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